Improving Profitability Through a Change in the Sales Policy for the Diagnostics and Reagents Business
First written in FY2016. 23 of 33 entries say "Advanced", first in FY2018-Q2. Latest entry: 2026-08-07.
30 other companies' latest entry also says "Advanced".
- 2026-08-07AdvancedEarnings
「Operating income increased 116.2% year on year to ¥118.172 million, owing to higher sales of high-margin products compared with the previous year’s first quarter.」
Operating income from the antibody-related business rose 116.2% year on year, driven by higher sales of high-margin products. - FY2026AdvancedAnnual report
「Although personnel and manufacturing costs and other expenses increased, operating income from this business rose 35.4% year on year to ¥281.886 million, owing to higher sales of high-margin products, stronger cost controls, and efforts to improve operating efficiency.」
In the antibody-related business, operating profit increased 35.4% year on year to ¥281.886 million due to higher sales of high-margin products, strengthened cost management and improved business efficiency. - FY2026-H1AdvancedAnnual report
「Operating profit increased 111.7% year on year to ¥142.447 million, due to higher revenue, lower costs following the closure of the Akita Analysis Center in Akita Prefecture and consolidation into the IBL Analysis Center in Gunma Prefecture, higher productivity, and efforts to control costs.」
In the antibody-related business, operating profit increased 111.7% year on year to ¥142.447 million due to higher revenue, lower costs from consolidating the Akita Analysis Center into the IBL Analysis Center, higher productivity and cost controls. - FY2025AdvancedAnnual report
「Although personnel expenses, manufacturing costs and other costs increased, operating profit increased 93.1% year on year to ¥208.180 million due to substantially higher revenue, strengthened cost management and efforts to improve business efficiency.」
In the antibody-related business, operating profit increased 93.1% year on year to ¥208.180 million due to higher revenue, strengthened cost management and improved business efficiency. - FY2025-H1AdvancedAnnual report
「Operating profit increased 310.8% year on year to ¥67.279 million, due to higher revenue and efforts to control costs.」
In the antibody-related business, operating profit increased 310.8% year on year to ¥67.279 million due to higher revenue and cost controls, indicating improved profitability. - FY2024AdvancedAnnual report
「Operating profit in the business was ¥107.816 million, up 52.9% year on year.」
Operating profit in the antibody-related business was ¥107.816 million, up 52.9% year on year. - FY2024-Q3WorsenedAnnual report
「Although tax costs declined significantly as a result of the reduction in capital, personnel expenses and manufacturing costs increased. In addition, SG&A expenses rose year on year because servers and other equipment were replaced, with the full amount expensed, to strengthen information management. As a result, operating profit in the business was ¥14.306 million, down 52.9% year on year.」
The antibody-related business remained profitable, but operating profit declined 52.9% year on year to ¥14.306 million due to higher personnel and manufacturing costs and increased SG&A expenses resulting from the replacement of servers and other equipment. - FY2024-Q2AdvancedAnnual report
「Although personnel expenses, manufacturing costs and other costs increased substantially year on year, operating profit increased significantly from the previous year because revenue from the company's own high-margin products rose substantially and tax costs declined significantly as a result of the reduction in capital. As a result, operating profit in the business was ¥17.706 million, compared with an operating loss of ¥46.537 million in the same period of the previous year.」
The antibody-related business moved from an operating loss of ¥46.537 million in the same period of the previous year to operating profit of ¥17.706 million, due to higher sales of its own high-margin products and lower tax costs. - FY2024-Q1AdvancedAnnual report
「Diagnostic reagent services 159,761 +26,841 +20.2 45,591 +16,453 +56.8」
Diagnostic reagent services recorded revenue of ¥159.761 million, up 20.2% year on year, and operating profit of ¥45.591 million, up 56.8%, indicating continued improvement in profitability. - FY2023AdvancedAnnual report
「As a result, operating profit in the business was ¥152.132 million, compared with an operating loss of ¥14.958 million in the same period of the previous year.」
The antibody-related business moved from an operating loss in the same period of the previous year to operating profit, recording operating profit of ¥152.132 million. Improved profitability became evident through higher sales volumes and expense controls. - FY2023-Q3AdvancedAnnual report
「As a result, revenue was ¥554.909 million, up 23.8% year on year, while operating profit improved substantially to ¥18.887 million, compared with an operating loss of ¥136.678 million in the same period of the previous year.」
The consolidated operating result moved from an operating loss in the same period of the previous year to operating profit of ¥18.887 million, due to increased overseas sales, optimisation of business activities, and a selective and focused approach to research and development. - FY2023-Q2AdvancedAnnual report
「Although investment funded by earnings from the business is considered desirable, profits improved substantially year on year partly because revenue increased and various expenses were kept under control by optimising business activities during the COVID-19 pandemic.」
The antibody-related business recorded revenue of ¥291.179 million and an operating loss of ¥5.910 million, a substantial improvement from the operating loss of ¥79.350 million in the same period of the previous year. The company cited optimisation of business activities and control of various expenses as factors behind the improvement in profitability. - FY2023-Q1AdvancedAnnual report
「Although investment funded by earnings from the business is considered desirable, profits improved substantially year on year partly because revenue increased and various expenses were kept under control by optimising business activities during the COVID-19 pandemic.」
In the antibody-related business, including Diagnostics and Reagents, profit improved substantially year on year due to higher revenue, optimisation of business activities and control of various expenses, resulting in segment operating profit of ¥8.932 million. - FY2022-Q1WorsenedAnnual report
「As a result, segment revenue was ¥95.894 million, up 4.9% year on year, and the operating loss was ¥22.357 million, compared with an operating loss of ¥16.584 million in the same period of the previous year.」
The Diagnostics and Reagents business recorded higher revenue, but the operating loss widened from ¥16.584 million in the same period of the previous year to ¥22.357 million due to higher expenses associated with research and development activities. - FY2021AdvancedAnnual report
「As a result, segment revenue was ¥494.099 million, up 4.9% year on year, and operating profit was ¥23.434 million, compared with an operating loss of ¥124.457 million in the same period of the previous year.」
The Diagnostics and Reagents business moved from an operating loss to operating profit, recording revenue of ¥494.099 million and operating profit of ¥23.434 million. - FY2021-Q3AdvancedAnnual report
「As a result, segment revenue was ¥343.447 million, up 12.0% year on year, and the operating loss was ¥2.844 million, compared with an operating loss of ¥25.567 million in the same period of the previous year.」
Revenue in the Diagnostics and Reagents business increased 12.0% year on year, and the operating loss narrowed from ¥25.567 million to ¥2.844 million. The company also cited lower sales department expenses, including through restrictions on business travel, as a factor in the improvement, but the business remained in the red. - FY2021-Q2AdvancedAnnual report
「As a result, segment revenue was ¥203.288 million, up 17.8% year on year, and the operating loss was ¥19.641 million, compared with an operating loss of ¥39.228 million in the same period of the previous year.」
Revenue in the Diagnostics and Reagents business increased 17.8% year on year, and the operating loss narrowed from ¥39.228 million to ¥19.641 million. However, the business remained in the red. - FY2021-Q1Operating loss narrowed, but losses continuedAnnual report
「As a result, segment revenue was ¥91.394 million, up 3.9% year on year, and the operating loss was ¥16.584 million, compared with an operating loss of ¥19.467 million in the same period of the previous year.」
Revenue in the Diagnostics and Reagents business increased 3.9% year on year, and the operating loss narrowed from ¥19.467 million to ¥16.584 million, but the business has not yet returned to profitability. - FY2020WorsenedAnnual report
「As a result, segment revenue was ¥471.203 million, versus ¥656.000 million under the medium-term plan, down 19.9% year on year, and the operating loss was ¥124.457 million, versus ¥147.000 million under the medium-term plan, compared with operating profit of ¥67.079 million in the same period of the previous year.」
The Diagnostics and Reagents business moved from operating profit in the previous year to an operating loss, while revenue fell 19.9% year on year. - FY2020-Q3WorsenedAnnual report
「As a result, segment revenue was ¥306.544 million, down 28.8% year on year, and the operating loss was ¥25.567 million, compared with operating profit of ¥88.502 million in the same period of the previous year.」
Revenue in the Diagnostics and Reagents business fell 28.8% year on year, and the business moved from operating profit of ¥88.502 million in the same period of the previous year to an operating loss of ¥25.567 million. - FY2020-Q2WorsenedAnnual report
「As a result, segment revenue was ¥172.576 million, down 35.0% year on year, and the operating loss was ¥39.228 million, compared with operating profit of ¥42.072 million in the same period of the previous year.」
Revenue in the Diagnostics and Reagents business fell 35.0% year on year, and the business moved from operating profit of ¥42.072 million in the same period of the previous year to an operating loss of ¥39.228 million. - FY2020-Q1WorsenedAnnual report
「As a result, segment revenue was ¥88.002 million, down 35.0% year on year, and the operating loss was ¥19.467 million, compared with operating profit of ¥15.795 million in the same period of the previous year.」
Revenue in the Diagnostics and Reagents business fell 35.0% year on year, and the business moved from operating profit of ¥15.795 million in the same period of the previous year to an operating loss of ¥19.467 million. The decline in revenue from EIA kits and BSE kits was a contributing factor. - FY2019Profitability maintained, but operating profit declinedAnnual report
「As a result, segment revenue was ¥588.014 million, down 2.9% year on year, and operating profit was ¥67.079 million, down 47.4%.」
The Diagnostics and Reagents business remained profitable, but revenue fell 2.9% year on year and operating profit declined 47.4%. - FY2019-Q3AdvancedAnnual report
「As a result, segment revenue was ¥430.267 million, up 7.9% year on year, and operating profit was ¥88.502 million, up 36.3% year on year. The business aims to continue generating stable profit.」
The diagnostics and research reagents business generated revenue of ¥430.267 million and operating profit of ¥88.502 million, with operating profit up 36.3% year on year. The company continues to target stable profit generation. - FY2019-Q1AdvancedAnnual report
「As a result, segment revenue was ¥135.435 million, up 33.9% year on year, and operating profit was ¥15.795 million, compared with an operating loss of ¥9.850 million in the same period of the previous year. The business aims to continue generating stable profit.」
The diagnostics and research reagents business moved from an operating loss in the same period of the previous year to operating profit of ¥15.795 million, and continues to target stable profit generation. - FY2018AdvancedAnnual report
「As a result, segment revenue was ¥605.745 million, up 8.9% year on year, and operating profit was ¥127.506 million, up 8.2%.」
The diagnostics and research reagents business generated full-year revenue of ¥605.745 million and operating profit of ¥127.506 million, recording higher revenue and profit. - FY2018-Q3AdvancedAnnual report
「As a result, segment revenue was ¥398.933 million, up 8.4% year on year, and operating profit was ¥64.954 million, up 23.6%. The business aims to continue increasing profit.」
The diagnostics and research reagents business generated revenue of ¥398.933 million and operating profit of ¥64.954 million, with operating profit up 23.6% year on year. The company continues to target higher profit. - FY2018-Q2AdvancedAnnual report
「As a result, segment revenue was ¥261.858 million, up 2.9% year on year, and operating profit was ¥46.086 million, up 2.6%. The business was profitable during the six-month period ended in the second quarter, and aims to maintain stable profitability for the full year.」
The diagnostics and research reagents business was profitable during the six-month period ended in the second quarter, posting operating profit of ¥46.086 million. The target of maintaining stable full-year profitability remains in place. - FY2018-Q1Full-year profitability target specifiedAnnual report
「The business aims to maintain stable profitability for the full year.」
In addition to the profitability improvement resulting from the previous sales policy, the company has specified a target of maintaining stable profitability for the full year in the diagnostics and research reagents business. - FY2016First statedAnnual report
「Profitability of research reagents has improved following a change in the sales policy.」
The company explained that profitability in the diagnostics and research reagents business improved through a change in its sales policy.